Proof-of-Concept Trial Confirms ZT-01’s Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes

Zucara Therapeutics Inc., a diabetes life sciences company developing the first therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), recently announced that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes (“T1D”).

Data from 18 subjects that completed all three hypoglycemic challenge (clamp) procedures demonstrated that nearly 90% of subjects had a meaningful increase in glucagon following ZT-01 compared to placebo. Compared to placebo, ZT-01 at 3 mg and 20 mg resulted in a mean 14 pg/mL and a 20 pg/mL change in peak glucagon from baseline, respectively (p<0.0001); while, on average, ZT-01 doubled the number of counter-regulatory events (an increase in blood glucose in hypoglycemia despite increasing insulin infusion). Of the 18 subjects completing 3 clamps, 16 showed a greater than 10 pg/mL increase in glucagon higher than placebo following one or both doses of ZT-01. There were no serious adverse events observed.

Zucara Therapeutics presented at the OBIO® Investment Summit.